Inactivated Influenza Vaccine Market Report for M&A, Expansion, and Competitive Benchmarking (2025–2034)

LONDON, GREATER LONDON, UNITED KINGDOM, June 17, 2025 /EINPresswire.com/ -- What Is The Growth Trajectory Of The Inactivated Influenza Vaccine Market?
Over recent years, the inactivated influenza vaccine market size has seen considerable growth. Figures predict a rise from $6.62 billion in 2024 to $7.21 billion in 2025, marking a compound annual growth rate CAGR of 8.9%. The growth during this period can be linked to several factors such as increased seasonal influenza outbreaks, government vaccination campaigns, a growing elderly population, improved public health awareness, and expanded healthcare infrastructure.

How Will The Inactivated Influenza Vaccine Market Expand In The Coming Years?
The strong potential remains in the extension period where the market size is expected to reach $9.99 billion in 2029, indicating a compound annual growth rate CAGR of 8.5%. Factors facilitating the progress in the forecast period encompass the rising demand for quadrivalent vaccines, expanding immunization programs, an escalating focus on pandemic preparedness, technological advancements in vaccine production, and burgeoning global vaccine access.
Key market trends shaping the forecast period include a shift toward cell-based vaccine production, a rising adoption of adjuvanted formulations, the integration of influenza vaccines with COVID-19 boosters, amplified demand in emerging markets, and the strategic move toward personalized vaccine development.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24251&type=smp

What Factors Are Accelerating The Inactivated Influenza Vaccine Market Growth?
It is expected that the rising government vaccination programs will fuel the expansion of the inactivated influenza vaccine market moving forward. Government vaccination programs have been growing due to increased public health awareness amongst populations. This leads to an elevated demand for immunization services and pushes governments to enhance vaccine accessibility and outreach initiatives.

Notably, government vaccination programs facilitate the administration of inactivated influenza vaccines by providing free or subsidized access to high-risk groups. This ensures fair immunization coverage and minimizes the impact of seasonal influenza. For example, in December 2023, the National Health Service, a UK-based government agency, initiated an NHS vaccine strategy for immunization goals. The strategy emphasizes community-based vaccination services, with targeted efforts for underserved and marginalized groups. Consequently, the rise of government vaccination programs serves as a pivotal driver propelling the inactivated influenza vaccine market's growth.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/inactivated-influenza-vaccine-global-market-report

Who Are The Major Players In The Inactivated Influenza Vaccine Market?
Several prominent companies are operating in the inactivated influenza vaccine market. Key players include giants such as Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis International, GlaxoSmithKline plc, Viatris Inc., CSL, Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Dalian Aleph Biomedical Co. Ltd., Hualan Biological Bacterin Co. Ltd, Changchun Biological, Jiangsu gdk Biotechnology Co., Ltd., KM Biologics, JoinHub Pharma, and Pharmika India Private Limited.

What Are The Significant Trends Emerging In The Inactivated Influenza Vaccine Market?
Leading companies in the market have turned their focus towards developing quadrivalent inactivated influenza vaccines to provide a broader scope of protection against four distinct strains of the influenza virus. A case in point is Zydus Lifesciences, an India-based pharmaceutical company, which made headlines in February 2025 by launching VaxiFlu-4. This quadrivalent inactivated influenza vaccine is designed to offer seasonal protection against four new virus strains by covering both influenza A and B strains, therefore diminishing the risk of vaccine mismatch and aiming to address seasonal flu outbreaks with an improved immune response bespoke to regional epidemiological patterns.

How Is The Inactivated Influenza Vaccine Market Segmented?
The inactivated influenza vaccine market is primarily segmented by vaccine type Trivalent Inactivated Influenza Vaccine TIIV and Quadrivalent Inactivated Influenza Vaccine QIIV, application Children, Adolescence, Adults, Elderly, by distribution channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Public Health Clinics, and end-users Healthcare Providers, Individuals, Government Organizations, Pharmaceutical Companies.

What Are The Regional Insights Into The Inactivated Influenza Vaccine Market?
From a geographic perspective, North America currently leads as the most extensive region in the inactivated influenza vaccine market as of 2024, with Asia-Pacific anticipated to be the fastest-growing region within the forecast period. The report covers in-depth insights on Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
Adult Vaccines Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Therapeutic BCG Vaccines Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Influenza Vaccines Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Take a deep dive into The Business Research Company. Offering over 15000+ data-rich reports from 27 industries encompassing 60+ geographies, The Business Research Company leads in delivering comprehensive, data-supported research and insights. With 1,500,000 datasets in their arsenal, their work is backed up by in-depth secondary research and distinctive insights from industry leaders, offering you all the information you need to stay ahead in the game.

Reach us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.